17-Jan-2025
Progyny Strengthens Leadership with New Director Appointment
TipRanks (Thu, 16-Jan 9:50 AM ET)
Progyny Appoints Healthcare Veteran Debra Morris to Board of Directors
Globe Newswire (Thu, 16-Jan 9:00 AM ET)
Business Wire (Tue, 14-Jan 4:00 PM ET)
Business Wire (Tue, 14-Jan 9:00 AM ET)
Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference
Globe Newswire (Mon, 13-Jan 8:00 AM ET)
Cigna Healthcare Expands Access to Fertility and Family-Building Benefits and Services
PRNewswire (Mon, 13-Jan 8:00 AM ET)
Kuehn Law Encourages Investors of Progyny, Inc. to Contact Law Firm
PRNewswire (Tue, 7-Jan 9:20 PM ET)
PRNewswire (Wed, 18-Dec 8:33 PM ET)
Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
Globe Newswire (Wed, 18-Dec 10:42 AM ET)
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
Progyny trades on the NASDAQ stock market under the symbol PGNY.
As of January 17, 2025, PGNY stock price climbed to $21.00 with 2,214,712 million shares trading.
PGNY has a market cap of $1.79 billion. This is considered a Small Cap stock.
Last quarter Progyny reported $287 million in Revenue and $.40 earnings per share. This fell short of revenue expectation by $-10 million and exceeded earnings estimates by $.27.
In the last 3 years, PGNY traded as high as $53.10 and as low as $13.39.
The top ETF exchange traded funds that PGNY belongs to (by Net Assets): IJR, CALF, IWM, VTI, VB.
PGNY has underperformed the market in the last year with a return of -45.0%, while SPY returned +28.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PGNY shares. However, PGNY has outperformed the market in the last 3 month and 2 week periods, returning +25.9% and +19.3%, while SPY returned +3.0% and +1.0%, respectively. This indicates PGNY has been having a stronger performance recently.
PGNY support price is $19.92 and resistance is $21.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PGNY shares will trade within this expected range on the day.